Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease (SCD-TGA)
Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease
BILLOIR
200 participants
Sep 1, 2018
OBSERVATIONAL
Conditions
Summary
Sickle cell disease (SCD) is an inherited haemoglobinopathy disorder caused by mutations in HBB gene with amino-acid substitution on β globin chain. The consequence is synthesis of altered haemoglobin S (HbS) which polymerises in red blood cell (RBC) at deoxygenated state. SCD is associated with chronic haemolytic anaemia, vaso-occlusive crisis (VOC) leading to frequent hospitalisation. The aim of the study was to to investigate whether a combination of routine laboratory biomarkers of haemolysis could be used to predict VOC development in confirmed SCD patients.
Eligibility
Inclusion Criteria1
- Sickle cell disease
Exclusion Criteria3
- <18 years
- pregnancy
- Patient under protective guardianship or curatorship
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Erythrocytic parameters and thrombin generation assay measurement
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05376046